Scarica l'app Stockscreener
808.86
0.50%
-3.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Truist Securities Raises Price Target for REGN to $820, Maintains Buy Rating | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $820.00 Price Target at Truist Financial - MarketBeat
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Benzinga
Noesis Capital Mangement Corp Has $11.90 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
KLP Kapitalforvaltning AS Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
MassMutual Private Wealth & Trust FSB Buys 1,267 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diabetic Retinopathy Market to Witness Remarkable Growth With - openPR.com
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - MSN
Analyst Upgrades And Short-Interest Drop Might Change The Case For Investing In Regeneron (REGN) - Yahoo Finance
Regeneron Just Moved From Underperform To BuyHere's Why - Benzinga
This Lowe's Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday (CORRECTED) - Benzinga
Regeneron Stock Lagged Behind the S&P 500 Last Year. Why This Firm Moved Off the Sidelines. - Barron's
Regeneron upgraded at BoA on Eylea HD, Dupixent, and pipeline - Seeking Alpha
Regeneron Science Talent Search: 33 Long Island students named semifinalists - Newsday
Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalysts - Proactive financial news
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Finviz
Regeneron Pharma gains as BofA upgrades rating - TradingView — Track All Markets
Why Regeneron (REGN) Stock Is Trading Up Today - Finviz
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 12-Month High After Analyst Upgrade - MarketBeat
Regeneron Pharmaceuticals stock hits 52-week high at $795.88 By Investing.com - Investing.com India
Regeneron Pharmaceuticals stock hits 52-week high at $795.88 - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Bank of America - MarketBeat
Analyst Upgrade: Regeneron Pharmaceuticals (REGN) Rating Boosted to Buy | REGN Stock News - GuruFocus
21 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know - Benzinga
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Merit Financial Group LLC Has $1.05 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diabetic Macular Edema Market to hit US$ 7.44 Billion by 2033 | Top - openPR.com
Will Regeneron Pharmaceuticals Inc. stock maintain dividend yield2026 world cup usa national team round of 32 key players low block defense group prediction preview - Улправда
Regeneron Upgraded From Underperform to Buy – Here’s the Reason - Bitget
The Truth About Regeneron Pharm: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Looking at the Latest Short Interest Trends for Regeneron Pharmaceuticals Inc - Bitget
Peering Into Regeneron Pharmaceuticals Inc's Recent Short Interest - Benzinga
How Dupixent’s New Pediatric Asthma Nod in Japan Will Impact Regeneron Pharmaceuticals (REGN) Investors - simplywall.st
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Regeneron Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth - TradingView — Track All Markets
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson - sharewise.com
Regeneron Pharmaceuticals Inc RGO Stock Analysis and ForecastStock Screening Results & Big Gains Low Budget - earlytimes.in
Intellia Stock Declines Around 55% in 3 Months: Here's Why - TradingView — Track All Markets
Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026 - The Globe and Mail
Regeneron Pharmaceuticals Inc Stock Analysis and ForecastAnalyst Downgrades & Small Budget Capital Gains - earlytimes.in
Allspring Global Investments Holdings LLC Sells 6,253 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Navigating the Biotech Giant’s Growth Potential and Analyst Ratings - DirectorsTalk Interviews
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum - simplywall.st
Regeneron (REGN) Valuation Check After Japan Clears Dupixent for Pediatric Severe Asthma Expansion - Yahoo Finance
Regeneron Shares Maintain Momentum as Key Catalysts Align - AD HOC NEWS
Financiere des Professionnels Fonds d investissement inc. Acquires Shares of 3,171 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Who Owns Regeneron Pharmaceuticals? Top Shareholders and Recent Insider Trades - TIKR.com
Brookwood Investment Group LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - MSN
Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week - MSN
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 - The Manila Times
Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host ... - Caledonian Record
In Case You Missed It: Trial Updates, FDA Approvals & Rejections - Citeline News & Insights
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MSN
Generate Investment Management Ltd Acquires 6,778 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
3 Reasons to Avoid REGN and 1 Stock to Buy Instead - FinancialContent
Simplify Asset Management Inc. Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Rockland IDA votes to terminate and recapture Regeneron incentives - Westfair Communications
J&J Bispecific For Atopic Dermatitis Fails To Pass Muster - Citeline News & Insights
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
TB Alternative Assets Ltd. Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bellecapital International Ltd. Buys 2,276 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cwm LLC Has $30.03 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
6.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):